Researchers have identified new treatments for liver diseases, including the use of melatonin receptors to slow disease progression. Additionally, scientists have discovered potential therapeutic targets for acetaminophen-related liver damage and a link between non-coding RNA and alcoholic liver disease.
Scientists have found that a specific protein called thrombospondin-2 (TSP2) is elevated in wounds of patients with diabetes and contributes to delayed wound healing. Removing or inhibiting TSP2 from mice with diabetes led to improved wound healing, suggesting it could be a target for new treatments.
Research suggests that tiny differences in patient position during radiotherapy can lead to reduced survival chances, particularly when tumours are close to vital organs like the heart. Tightening treatment guidelines could improve survival rates by ensuring more accurate patient positioning.
Researchers found piperacillin-tazobactam significantly less effective than meropenem in treating BSI caused by ceftriaxone-resistant E. coli and K. pneumoniae. The study concluded that piperacillin-tazobactam should be avoided when treating these organisms due to its inferior efficacy.
Researchers have made significant breakthroughs in treating pancreatic, colon and breast cancers, as well as developing new pain treatments for chemotherapy-induced peripheral neuropathy. A new compound has shown promise in targeting cancer cell death pathways, while indomethacin has been found to inhibit colon cancer growth.
A new study found that patients with cellulitis treated for six days experienced faster and more frequent relapses at 90 days compared to those treated for 12 days. The study suggested that elderly hospitalized patients with comorbidity may benefit from shorter therapy duration.
Researchers discovered a gene linked to high fatality rates in P. aeruginosa BSI, which could be used as a novel prognostic biomarker. The helP gene was identified through genetic characteristics and gene expression data of P. aeruginosa strains from patients with a bloodstream infection.
A seven-day antibiotic course was shown to be non-inferior to a 14-day course for treating Gram-negative bacteraemia, with similar patient outcomes and faster recovery. The study found reduced antibiotic days and improved return to daily activities in the shorter treatment group.